This is supported by the fact that T1DM is an adverse effect associated with PD‐1 inhibitors, like nivolumab, while the use of CTLA‐4 inhibitor ipilimumab as monotherapy was not associated with T1DM in clinical trials [3, 4]. Here, CTLA4 is linked to type 1 diabetes mellitus.